Masaaki Miyachi
Nagoya University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masaaki Miyachi.
Hypertension | 2009
Masaaki Miyachi; Hiroki Yazawa; Mayuko Furukawa; Koji Tsuboi; Masafumi Ohtake; Takao Nishizawa; Katsunori Hashimoto; Toyoharu Yokoi; Tetsuhito Kojima; Takashi Murate; Mitsuhiro Yokota; Toyoaki Murohara; Yasuo Koike; Kohzo Nagata
The clinical efficacy of exercise training in individuals with heart failure is well established, but the mechanism underlying such efficacy has remained unclear. An imbalance between cardiac hypertrophy and angiogenesis is implicated in the transition to heart failure. We investigated the effects of exercise training on cardiac pathophysiology in hypertensive rats. Dahl salt-sensitive rats fed a high-salt diet from 6 weeks of age were assigned to sedentary or exercise (swimming)-trained groups at 9 weeks. Exercise training attenuated the development of heart failure and increased survival, without affecting blood pressure, at 18 weeks. It also attenuated left ventricular concentricity without a reduction in left ventricular mass or impairment of cardiac function. Interstitial fibrosis was increased and myocardial capillary density was decreased in the heart of sedentary rats, and these effects were attenuated by exercise. Exercise potentiated increases in the phosphorylation of Akt and mammalian target of rapamycin observed in the heart of sedentary rats, whereas it inhibited the downregulation of proangiogenic gene expression apparent in these animals. The abundance of the p110&agr; isoform of phosphatidylinositol 3-kinase was decreased, whereas those of the p110&ggr; isoform of phosphatidylinositol 3-kinase and the phosphorylation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase were increased, in the heart of sedentary rats, and all of these effects were prevented by exercise. Thus, exercise training had a beneficial effect on cardiac remodeling and attenuated heart failure in hypertensive rats, with these effects likely being attributable to the attenuation of left ventricular concentricity and restoration of coronary angiogenesis through activation of phosphatidylinositol 3-kinase(p110&agr;)-Akt-mammalian target of rapamycin signaling.
Journal of Hypertension | 2008
Mayuko Kato; Rei Shibata; Koji Obata; Masaaki Miyachi; Hiroki Yazawa; Koji Tsuboi; Takashi Yamada; Takao Nishizawa; Akiko Noda; Xian Wu Cheng; Takashi Murate; Yasuo Koike; Toyoaki Murohara; Mitsuhiro Yokota; Kohzo Nagata
Objective Cardiac hypertrophy is common in diabetes and an independent risk factor for cardiac morbidity and mortality. We investigated the effects of pioglitazone on cardiac hypertrophy and hypertrophic signaling in Dahl salt-sensitive hypertensive rats. Methods Dahl salt-sensitive rats were fed a high-salt diet from 7 weeks of age and treated with pioglitazone (2.5 mg/kg per day) or vehicle from 7 to 11 weeks. Results The vehicle-treated rats developed left ventricular hypertrophy and fibrosis as well as left ventricular diastolic dysfunction. The serum level of adiponectin and the phosphorylation of AMP-activated protein kinase in the myocardium did not differ between the vehicle-treated rats and control rats maintained on a normal diet. The phosphorylation of Akt, mammalian target of rapamycin, and p70S6 kinase as well as the total protein content were increased in the heart of vehicle-treated rats compared with control rats, and these changes were blocked by treatment with pioglitazone. Pioglitazone treatment also ameliorated left ventricular hypertrophy and fibrosis, improved diastolic function, and increased both the serum adiponectin concentration and the level of AMP-activated protein kinase phosphorylation in the heart. Conclusions Long-term administration of pioglitazone attenuated left ventricular hypertrophy and fibrosis as well as inhibited phosphorylation of mammalian target of rapamycin and p70S6 kinase in the heart of hypertensive rats. The beneficial cardiac effects of pioglitazone are likely attributable, at least partly, both to the activation of AMP-activated protein kinase signaling through stimulation of adiponectin secretion and to the inhibition of Akt signaling.
European Journal of Pharmacology | 2009
Takashi Yamada; Kohzo Nagata; Xian Wu Cheng; Koji Obata; Masako Saka; Masaaki Miyachi; Keiko Naruse; Takao Nishizawa; Akiko Noda; Hideo Izawa; Masafumi Kuzuya; Kenji Okumura; Toyoaki Murohara; Mitsuhiro Yokota
The Ca2+ channel blocker nifedipine has been reported to reduce the rate of new overt heart failure. We investigated the effects of nifedipine on left ventricular remodeling, oxidative stress, and gene expression in the failing heart of Dahl salt-sensitive (DS) rats. DS rats fed a high-salt diet from 7 weeks of age were treated with a non-antihypertensive (1 mg/kg per day, Nif-L) or mild-antihypertensive dose of nifedipine (3 mg/kg per day, Nif-H) or with vehicle (Vehicle) from 12 to 19 weeks. Marked left ventricular hypertrophy and fibrosis were apparent and the ratio of collagen type I to type III mRNA levels and the activity of matrix metalloproteinase (MMP)-2 and its mRNA expression in the myocardium were increased in Vehicle at 19 weeks in comparison with Control. Load-induced left ventricular hypertrophy was reduced in Nif-H, but not in Nif-L, relative to that in Vehicle. Treatment with either dose of nifedipine reduced the extent of fibrosis, the collagen type I to type III mRNA ratio, and MMP-2 activity and its mRNA expression compared with those in Vehicle. The decrease in the ratio of reduced to oxidized glutathione and the increase in NADPH oxidase activity apparent in the left ventricle of Vehicle were also inhibited by nifedipine at both doses. Nifedipine thus inhibited the development of left ventricular fibrosis and diastolic heart failure in DS rats, independently of its antihypertensive effect. The overall protective action of nifedipine is likely attributable to its antioxidant effect as well as to its antihypertensive action.
Journal of Cardiac Failure | 2007
Hiroki Yazawa; Masaaki Miyachi; Mayuko Furukawa; Keiji Takahashi; Miwa Takatsu; Koji Tsuboi; Masafumi Ohtake; Tamayo Murase; Takuya Hattori; Yosuke Kato; Toyoaki Murohara; Kohzo Nagata
BACKGROUND The biologic response to angiotensin-converting enzyme (ACE) inhibitors may be influenced by the local environment. The effect of ACE inhibition on coronary angiogenesis was investigated in a rat model of hypertensive heart failure. METHODS AND RESULTS Dahl salt-sensitive (DS) rats fed a high-salt diet from 6 weeks of age were treated with a nonantihypertensive dose of the ACE inhibitor perindopril or vehicle from 9 to 18 weeks. Treatment of rats with perindopril attenuated the heart failure as well as cardiac hypertrophy and fibrosis that were manifest in the vehicle-treated animals. Myocardial capillary density as well as the expression of the bradykinin B(2) receptor, endothelial nitric oxide synthase, and vascular endothelial growth factor were reduced in the heart of vehicle-treated rats compared with that of nonhypertensive control rats, and all of these changes were attenuated by treatment with perindopril. CONCLUSIONS These results indicate that ACE inhibition by perindopril promotes myocardial capillary formation as well as attenuates cardiac remodeling and failure in a manner independent from the antihypertensive effect of the drug in DS hypertensive rats. The beneficial cardiac effects of perindopril were associated with activation of the bradykinin-nitric oxide pathway in the heart.
Hypertension Research | 2014
Takuya Hattori; Tamayo Murase; Yukino Sugiura; Kai Nagasawa; Keiji Takahashi; Masafumi Ohtake; Mayuko Ohtake; Masaaki Miyachi; Toyoaki Murohara; Kohzo Nagata
The mineralocorticoid aldosterone regulates sodium and water homeostasis in the human body. The combination of excess aldosterone and salt loading induces hypertension and cardiac damage. However, little is known of the effects of aldosterone on blood pressure and cardiac pathophysiology in the absence of salt loading. We have now investigated the effects of salt status and blockade of mineralocorticoid receptors (MRs) on cardiac pathophysiology in uninephrectomized Sprague-Dawley rats implanted with an osmotic minipump to maintain hyperaldosteronism. The rats were fed a low-salt (0.0466% NaCl in chow) or high-salt (0.36% NaCl in chow plus 1% NaCl in drinking water) diet in the absence or presence of treatment with a subdepressor dose of the MR antagonist spironolactone (SPL). Aldosterone excess in the setting of low salt intake induced substantial cardiac remodeling and diastolic dysfunction without increasing blood pressure. These effects were accompanied by increased levels of oxidative stress and inflammation as well as increased expression of genes related to the renin–angiotensin and endothelin systems in the heart. All of these cardiac changes were completely blocked by the administration of SPL. On the other hand, aldosterone excess in the setting of high salt intake induced hypertension and a greater extent of cardiac injury, with the cardiac changes being only partially attenuated by SPL in a manner independent of its antihypertensive effect. The combination of dietary salt restriction and MR antagonism is thus a promising therapeutic option for the management of hypertensive patients with hyperaldosteronism or relative aldosterone excess.
Hypertension | 2009
Masaaki Miyachi; Kohzo Nagata
We thank Thornton and Hess1 for their comments on our article2 and its editorial commentary.3 We understand the possible effects of lactate on mitochondrial function. Indeed, recent data place lactate as an active metabolite capable of moving between cells, tissues, and organs, where it may be oxidized as a fuel or reconverted to form pyruvate or glucose. Lactate is also capable of entering cells via the monocarboxylate transporter protein shuttle system. However, our concern is that data on mitochondrial dysfunction acquired in patients with end-stage heart failure do not help us in understanding the involvement of mitochondria in the …
Nagoya Journal of Medical Science | 2013
Takuya Hattori; Tamayo Murase; Erika Iwase; Keiji Takahashi; Masafumi Ohtake; Koji Tsuboi; Mayuko Ohtake; Masaaki Miyachi; Toyoaki Murohara; Kohzo Nagata
Nagoya Journal of Medical Science | 2014
Masafumi Ohtake; Takuya Hattori; Tamayo Murase; Keiji Takahashi; Miwa Takatsu; Mayuko Ohtake; Masaaki Miyachi; Shogo Watanabe; Xian Wu Cheng; Toyoaki Murohara; Kohzo Nagata
Japanese Circulation Journal-english Edition | 2008
Hiroki Yazawa; Masaaki Miyachi; Mayuko Kato; Ayako Hukata; Koji Tuboi; Yurie Kasai; Yuriko Kato; Takao Nishizawa; Katsunori Hashimoto; Akiko Noda; Yasuo Koike; Mituhiro Yokota; Kohzo Nagata
Archive | 2011
Hiroki Yazawa; Masaaki Miyachi; Mayuko Furukawa; Keiji Takahashi; Miwa Takatsu; Koji Tsuboi; Masafumi Ohtake; Tamayo Murase; Takuya Hattori; Yosuke Kato; Toyoaki Murohara; Kohzo Nagata